SC

Scopus Biopharma IncOOTC SCPS Stock Report

Last reporting period 30 Jun, 2023

Updated 12 Nov, 2024

Last price

Market cap $B

0

Micro

Exchange

OOTC - OTC

SCPS Stock Analysis

SC

Uncovered

Scopus Biopharma Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0

Dividend yield

Shares outstanding

21.094 B

Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of transformational therapeutics targeting serious diseases with unmet medical needs. The company is headquartered in New York City, New York and currently employs 9 full-time employees. The company went IPO on 2020-12-16. The firm is focused on the development of its immuno-oncology programs. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The firm is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Its pipeline also includes MRI-1867, which is a cannabinoid receptor mediating compound for the treatment of systemic sclerosis.

View Section: Eyestock Rating